These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27221729)

  • 1. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
    Nijenhuis CM; Hellriegel E; Beijnen JH; Hershock D; Huitema AD; Lucas L; Mergui-Roelvink M; Munteanu M; Rabinovich-Guilatt L; Robertson P; Rosing H; Spiegelstein O; Schellens JH
    Invest New Drugs; 2016 Oct; 34(5):565-74. PubMed ID: 27221729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolite profiling of
    Nijenhuis CM; Lucas L; Rosing H; Robertson P; Hellriegel ET; Schellens JH; Beijnen AJ
    Xenobiotica; 2016 Dec; 46(12):1122-1132. PubMed ID: 26998885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
    Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.
    Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH; Gorman SH; Burke SM; Campbell DA; Chapple MW; Yousey TH; Mulvana DE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():152-9. PubMed ID: 26319804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
    Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
    Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
    Quintás-Cardama A; Cortes J
    IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
    Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
    Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
    Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omacetaxine mepesuccinate for the treatment of leukemia.
    Kim TD; Frick M; le Coutre P
    Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Damlaj M; Lipton JH; Assouline SE
    Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
    Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
    Dubbelman AC; Rosing H; Darwish M; D'Andrea D; Bond M; Hellriegel E; Robertson P; Beijnen JH; Schellens JH
    Drugs R D; 2013 Mar; 13(1):17-28. PubMed ID: 23322528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
    Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and excretion of
    van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Narayanan V; Gutman JA; Pollyea DA; Jimeno A
    Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Mass Balance Study of
    Yu Y; Chung CH; Plotka A; Quinn K; Shi H; Pápai Z; Nguyen L; Wang D
    J Clin Pharmacol; 2019 Sep; 59(9):1195-1203. PubMed ID: 30964553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.